Term
|
Definition
| bind and kill tumor cells; binds to specific antigen on tumor cell, kills tumor by fixing complement, but ADCC, osonize, deliver cytotoxic or radioisotope drug to tumor |
|
|
Term
| Anti-CD20, Anti-Her2, Denileukin diftitox, Bretuximab vendotin, Trastuzumab (Herceptin) |
|
Definition
|
|
Term
|
Definition
| B cell specific; used for non-Hodgkin's lymphoma, other leukemias expressing antigen, malignant B cells |
|
|
Term
|
Definition
|
|
Term
|
Definition
| Growth factor receptor, a member of epidermal growth factor receptor family, expressed at high levels on some breast cancers, Her2 is also overexpressed on Gastric cancer |
|
|
Term
|
Definition
| Anti-Her2 mAb; drives apoptosis when binding to cancer cells and activating ADCC |
|
|
Term
| Bretuximab vendotin (Adcetris) |
|
Definition
| another andtibody conjugate, binding CD30 a protein found on surface of some lymphocytes, including a number of lymphomas. mAb is conjugated to a cytotoxic drug (auristatin). |
|
|
Term
| Denileukin diftitox (Ontak) |
|
Definition
| recombinant IL2 conjugated to diphtheria toxin. IL2 binds to CD25 = the high affinity proportion of the IL 2 receptor expressed on activated T cells; Diphtheria toxin kills the target cell; Used for leukemias and lymphomas where cancerous white blood cell expresses CD25 |
|
|
Term
| Ipilimumab (yervoy); cellular immunotherapy and immunostimulants |
|
Definition
| Promote T cell activation by blocking CTLA4; used for malignant melanoma |
|
|
Term
| cellular immunotherapy and immunostimulants |
|
Definition
| Ipilimumab (yervoy), Sipuleucel-T (Provenge) |
|
|
Term
|
Definition
| cancer vaccine; autologous cellular immunotherapy in which activates T cells with TCR specific for prostate cancer antigen (PAP); used for prostate cancer |
|
|
Term
|
Definition
| prostatic acid phosphatase that is present on many cancer prostatic cells |
|
|
Term
|
Definition
| IL-2 (Aldesleukin), IFN alpha |
|
|
Term
|
Definition
| severe side effects, shock and death |
|
|
Term
|
Definition
| MOA not fully known but activates T cells which act on tumor cells to slow proliferation |
|
|
Term
| Tyrosine kinase inhibitors |
|
Definition
| Imatinib (Gleevec), ii. Erlotinib (Tarceva), Cetuximab (Erbitux) anti-EGFR |
|
|
Term
|
Definition
| enzymes that phos proteins (ATP), and others initiates signaling cascades that regulate many cellular functions; prolif, survival, motility, differentiation, angiogenisis |
|
|
Term
| tyrosine kinase receptors |
|
Definition
| VEGFR (vascular endothelial), EGFR (epidermal), PDGRFR (platelet derived, ERB (Her-2 human epidermal GFR), FGFR (fibroblast) |
|
|
Term
| Tyrosine kinase non-receptor |
|
Definition
|
|
Term
|
Definition
| Used for chronic myelogenous leukemia (CML) and other leukemias that are BCL-ABL+ or Ph+; selective for BCL-ABL and prevents ATP from binding |
|
|
Term
|
Definition
| binds/ blocks intracellular site on Epidermal GFR, blocking proliferation, inhibits angiogenesis |
|
|
Term
|
Definition
|
|
Term
| Cetuximab (Erbitux) anti-EGFR |
|
Definition
|
|
Term
|
Definition
| Bortezomib (Velcade) and Carfilzomib (kyprolis) |
|
|
Term
|
Definition
| barrel-shaped enzyme complex to degrade proteins; clearance of obsolete, damaged/ abnormal proteins, responsible for antigen presentation, regulates proteins that affect cell cycle apoptosis |
|
|
Term
| NFKB, Caspases, Bcl, cyclins |
|
Definition
|
|
Term
| Bortezomib (Velcade) and Carfilzomib (kyprolis) |
|
Definition
| used for multiple myeloma; constipate plasma cell myeloma, abnormal proteins build up in the cell that can't be cleared/ recycled and this in turn signals cell to die; block activation of NFKB by preventing degradation of the inhibitor protein attached to NFKB |
|
|
Term
|
Definition
| trascription factor, and when activated it promotes IL-6 which drive cell prolif and activates cell adhesion molecules which sticks tumor cells to the bone marrow cells and promotes GEF release stimulating angiogenesis |
|
|
